SLVM:NYSESylvamo Corporation Analysis
Data as of 2026-05-01 - not real-time
$42.73
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Sylvamo (SLVM) is trading at $42.73, just above the computed support of $39.61 and below the resistance of $44.54, giving it limited upside on the short‑term chart. The MACD histogram is positive (0.17) and the line sits above the signal, indicating a modest bullish momentum despite the overall bearish trend flag. RSI is neutral at 51, suggesting the stock is neither overbought nor oversold. Volume is increasing, which could support a breakout toward the resistance level. On the fundamentals side, the company offers an attractive 4.21% dividend yield with a payout ratio of 55.6%, and the dividend appears sustainable given positive operating cash flow. Valuation metrics are compelling: a trailing PE of 13.2, a forward PE of 7.3, and a DCF‑derived fair value of $43.12 place the current price slightly below intrinsic value, implying upside.
However, revenue has contracted 8.2% year‑over‑year and the firm carries a high debt‑to‑equity ratio of 94.7%, which adds balance‑sheet risk. Free cash flow is marginally negative (-$16.5 M) and the sector faces medium regulatory and commodity‑price pressures. Analyst coverage is limited but positive, with four analysts rating the stock as “Buy” and a median price target of $56.5, representing roughly 30% upside. The market sentiment is extremely greedy (Fear‑Greed Index 90.9), suggesting momentum may be supporting the price. Upcoming Q1 earnings on May 8 will be a key catalyst to confirm whether the bullish technical signals translate into improved earnings guidance. In summary, the stock appears undervalued with solid dividend income, but investors should monitor earnings and leverage before committing larger positions.
However, revenue has contracted 8.2% year‑over‑year and the firm carries a high debt‑to‑equity ratio of 94.7%, which adds balance‑sheet risk. Free cash flow is marginally negative (-$16.5 M) and the sector faces medium regulatory and commodity‑price pressures. Analyst coverage is limited but positive, with four analysts rating the stock as “Buy” and a median price target of $56.5, representing roughly 30% upside. The market sentiment is extremely greedy (Fear‑Greed Index 90.9), suggesting momentum may be supporting the price. Upcoming Q1 earnings on May 8 will be a key catalyst to confirm whether the bullish technical signals translate into improved earnings guidance. In summary, the stock appears undervalued with solid dividend income, but investors should monitor earnings and leverage before committing larger positions.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Upcoming Q1 earnings release on May 8
- Price positioned near support with bullish MACD
- High dividend yield providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued relative to DCF fair value and analyst price targets
- Attractive forward PE of 7.3 indicating earnings upside
- Sustainable dividend yield above 4%
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Consistent dividend income with reasonable payout ratio
- Potential industry consolidation improving pricing power
- Long‑term upside of ~30‑40% based on median analyst targets
Key Metrics & Analysis
Financial Health
Revenue Growth-8.20%
Profit Margin3.94%
P/E Ratio13.2
ROE14.56%
ROA5.80%
Debt/Equity94.72
P/B Ratio1.7
Op. Cash Flow$268.0M
Free Cash Flow$-16500000
Technical Analysis
TrendBearish
RSI51.0
Support$39.61
Resistance$44.54
MA 20$42.43
MA 50$42.85
MA 200$45.53
MACDBullish
VolumeIncreasing
Fear & Greed Index90.93
Valuation
Fair Value$43.12
Target Price$59.50
Upside/Downside39.25%
GradeUndervalued
TypeValue
Dividend Yield4.21%
Risk Assessment
Beta0.79
Volatility33.48%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.